EQUITY RESEARCH MEMO
Great Bay Bio
Generated 5/25/2026
Executive Summary
Conviction (model self-assessment)60/100
Great Bay Bio is a Chinese biotechnology company founded in 2014, headquartered in Zhuhai, with a focus on discovering and developing antibody-based therapeutics for oncology and immune disorders. The company leverages cutting-edge technologies to generate fully human antibodies with high affinity and specificity, aiming to deliver innovative biologic drugs that provide improved therapeutic options. With a pipeline in Phase 1, Great Bay Bio is positioned to address significant unmet medical needs in cancer and autoimmune diseases, capitalizing on China's rapidly growing biotech ecosystem.
Upcoming Catalysts (preview)
- Q4 2026Phase 1 clinical data readout for lead antibody candidate50% success
- Q2 2026Strategic partnership or licensing deal for pipeline programs40% success
- Q3 2026IND filing for a novel antibody therapy in immune disorders60% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)